Study
medication: monoclonal
anti-PD-1 antibody.
We invite adult male and
female patients with:
- Histological verificate nonresectable or metastatic non-small cells lung cancer
- Radiological approved disease progression after chemotherapy against platinum-based drugs
- Deficit of mutation EGFR or ALK
- Deficit of progressing secondary tumor in axion (central nervous system)